Atea Pharmaceuticals (AVIR) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Turn Therapeutics (TTRX) over the past year, gaining 66.3% versus a gain of 62.7%. Atea Pharmaceuticals is the larger company by market cap ($413.5 million vs $345.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | TTRX |
|---|---|---|
| Share price | $5.16 | $11.39 |
| Market cap | $413.46M | $345.89M |
| 1-day change | +2.89% | -5.87% |
| YTD return | +44.40% | +189.09% |
| 1-year return | +66.29% | +62.71% |
| 5-year return | -86.88% | — |
| EPS (TTM) | $-2.09 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $16.45 |
| 52-week low | $2.87 | $2.57 |
| Distance from 52-week high | -20.08% | -30.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.74% | +119.49% |
| Average volume | 298.38K | 110.43K |
| Shares outstanding | 80.20M | 30.37M |
| Employees | 55 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
AVIR vs TTRX FAQ
Which is bigger, Atea Pharmaceuticals or Turn Therapeutics?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $413.46M compared with $345.89M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, AVIR or TTRX?
AVIR returned +66.29% over the past 12 months, compared with +62.71% for TTRX (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.